Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports

Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports Elisabeth MahaseThe antiviral drug molnupiravir reduced the risk of admission to hospital or death by around 50% in non-hospitalised adults who had mild to moderate covid-19 and were at risk of poor outcomes, Merck Sharp and Dohme (MSD) has reported.